Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds

Figure 7

Percent change of DHA + EPA blood cell membrane levels from baseline at week 4: after four weeks of treatment (A), blood cell membrane DHA and EPA levels were significantly increased in all SC411 doses (p<0.001) vs. baseline. 36 mg/Kg, 60 mg/Kg, and pooled treatments were also significantly increased vs. placebo (p<0.01).